Alpha-gal nanoparticles

Alpha-gal nanoparticles has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Mar 17, 2026: “The α-Gal Epitope (Galα1-3Galβ1-4GlcNAc) as Therapeutic Agent in Cancer Immunotherapy, Vaccine Effectiveness Amplification and Injured Tissue Regeneration”.

Intervention

2 papers study it2 findingsUpdated

See all 2 papers on alpha-gal nanoparticles

What did studies of alpha-gal nanoparticles find?

2

Studies of alpha-gal nanoparticles measured 2 outcomes: complement system and injured myocardium regeneration.

Complement system

upin humans1

1 study
  1. Alpha-gal nanoparticles activate complement system in injured tissue.

    “Anti-Gal binding to α-gal-presenting nanoparticles administered to wounds, into the post-myocardial infarction (MI) injured myocardium and into injured spinal cord, activates the complement system”

    Reviewin injured tissue

    The α-Gal Epitope (Galα1-3Galβ1-4GlcNAc) as Therapeutic Agent in Cancer Immunotherapy, Vaccine Effectiveness Amplification and Injured Tissue Regeneration

    International journal of molecular sciences

More on Complement system

Injured myocardium regeneration

upin mice1

1 study
  1. Alpha-gal nanoparticles improve injured myocardium regeneration in mice (post-MI in anti-Gal-producing mice).

    “This process results in near-complete regeneration of the injured myocardium within 14 days.”

    Reviewpost-MI in anti-Gal-producing micemyocardium14 days

    Lessons of Macrophage-Associated Heart Regeneration in Fish, Amphibians, and Neonatal Mice, Applied to Adult Mice: A Perspective on α-Gal Nanoparticles

    International journal of molecular sciences

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months